Amber-UI
Phase 1- Indications
- Mixed urinary incontinence, Urge urinary incontinence
Company intelligence / Profile preview
Amber Therapeutics
London, United Kingdomamber-tx.com ↗
- Ownership
- Private
- Employees
- ~15
- Development stage
- Phase 1
01
Overview
Amber Therapeutics develops the first fully implantable adaptive neuromodulation therapy for mixed urinary incontinence. Its lead product, Amber‑UI, uses closed-loop stimulation of the pudendal nerve via the Picostim DyNeuMo system. In early clinical trials (AURA‑2), the device showed good safety and strong efficacy signals—including complete resolution of incontinence episodes at six months for some patients. The company recently closed a $100 million Series A round to fund further development and US regulatory approval.
- Therapeutic areas
- NephrologyWomen's Health
- Modalities
- DeviceNeuromodulation therapyClosed-loop bioelectrical therapy
- Industry
- Implantable Medical Devices
02
Drug pipeline
1 asset03
Partnerships
University of Oxfordacademic collaborations exploring broader nervous system applications
Beyond the preview
Go deeper on Amber Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Amber Therapeutics.